arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2021-27-4-402-408arthyper-2139Research ArticleОБЗОРREVIEWБиологические и патофизиологические аспекты использования сортилина в диагностике атеросклерозаSortilin as a marker of atherosclerosis: biological and pathophysiological aspectshttps://orcid.org/0000-0003-1881-024XГубареваИ. В.GubarevaI. V.

Губарева Ирина Валерьевна — доктор медицинских наук, доцент, заведующая кафедрой внутренних болезней ФГБОУ ВО Самарский ГМУ Минздрава России.

Ул. Чапаевская, д.89, Самара, 443099

Irina V. Gubareva - MD, PhD, DSc, Assistant Professor, Head, Chair of Internal Diseases, Samara SMU.

Samara, 443099 Samara, 89 Chapaevskaya street. Tel.: 8(846)276–35–14

irigub@rambler.ruhttps://orcid.org/0000-0002-0844-6870ВуколоваЮ. Ю.VukolovaY. Y.

Вуколова Юлия Юрьевна — ассистент кафедры внутренних болезней ФГБОУ ВО Самарский ГМУ Минздрава России.

Ул. Чапаевская, д.89, Самара, 443099

Julia Yu. Vukolova - MD, Assistant, Chair of Internal Diseases, Samara SMU.

Samara, 443099 Samara, 89 Chapaevskaya street

yuliavuk@gmail.comФедеральное государственное бюджетное образовательное учреждение высшего образования Самарский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияSamara State Medical UniversityRussian Federation202119102021274402408Copyright © Губарева И.В., Вуколова Ю.Ю., 20212021Губарева И.В., Вуколова Ю.Ю.Gubareva I.V., Vukolova Y.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2139

Проявления субклинического атеросклероза служат независимым предиктором повышенного кардиоваскулярного риска, в том числе и у пациентов с артериальной гипертензией. В статье представлен обзор ключевых исследований по изучению патогенетической роли в атерогенезе и стратификации сердечно-сосудистого риска (ССР) пептида сортилина, который принадлежит к семейству вакуолярных сортирующих рецепторов типа I. Циркулирующий сортилин, действуя одновременно на липидные и нелипидные патогенетические механизмы атерогенеза, может служить ранним биомаркером ССР, что позволяет признать его одним из основных игроков в различных процессах атерогенеза и потенциальной терапевтической мишенью для коррекции дислипидемии и атеросклероза на субклиническом уровне.

Subclinical atherosclerosis is an independent predictor of increased cardiovascular risk, including patients with hypertension. The article provides an overview of the pathogenetic role in atherogenesis and cardiovascular risk stratification of sortilin peptide which belongs to the family of vacuolar sorting receptors of type I. Circulating sortilin impacts both lipid and non-lipid pathogenetic mechanisms of atherogenesis. It can serve as an early biomarker of cardiovascular risk and a potential therapeutic target for dyslipidemia management and atherosclerosis at subclinical level.

сердечно-сосудистый рискатеросклерозсортилинcardiovascular riskatherosclerosissortilinReferencesБойцов С. А., Шальнова С. А., Деев А. Д. Эпидемиологическая ситуация как фактор, определяющий стратегию действий по снижению смертности в Российской Федерации. Терапевтический архив. 2020;92(1):4–9. doi:10.26442/00403660.2020.01.000510Boytsov SA, Shalnova SA, Deev AD. The epidemiological situation as a factor determining the strategy for reducing mortality in the Russian Federation. Ter Arkh. 2020;92(1):4–9. doi:10.26442/00403660.2020.01.000510. In Russian.Метельская В. А., Шальнова С. А., Деев А. Д., Перова Н. В., Гомыранова М. В., Литинская О. А. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;19(1):15–23. doi:10.17116/profmed201619115-23Metelskaya VA, Shalnova SA, Deev AD, Perova NV, Gomyranova NV, Litinskaya OA et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina = Preventive Medicine. 2016;19(1):15–23. doi:10.17116/profmed201619115-23. In Russian.Кобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации. 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines. 2020. RussianJournal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.Weissler AM, Traditional risk factors for coronary heart disease. JAMA. 2004;291(3):299–300.Weissler AM, Traditional risk factors for coronary heart disease. JAMA. 2004;291(3):299–300.Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE poject. Eur Heart J. 2003;24(11):987–1003.Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE poject. Eur Heart J. 2003;24(11):987–1003.Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–2959.Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–2959.Langlois MR. Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. Clin Chem Lab Med. 2012;50(7):1169–1181.Langlois MR. Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. Clin Chem Lab Med. 2012;50(7):1169–1181.Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–138.Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–138.Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107–2116.Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358(20):2107–2116.Trabjerg E, Abu-Asad N, Wan Z, Kartberg F, Christensen S, Rand KD. Investigating the conformational response of the sortilin receptor upon binding endogenous peptide- and protein ligands by HDX–MS. Structure. 2019;27(7):1103–1113.e3. doi:10.1016/j.str.2019.04.006Trabjerg E, Abu-Asad N, Wan Z, Kartberg F, Christensen S, Rand KD. Investigating the conformational response of the sortilin receptor upon binding endogenous peptide- and protein ligands by HDX–MS. Structure. 2019;27(7):1103–1113.e3. doi:10.1016/j.str.2019.04.006Blondeau N, Béraud-Dufour S, Lebrun P, Hivelin C, Coppola T. Sortilin in glucose homeostasis: from accessory protein to key player? Front Pharmacol. 2019;9:1561. doi:10.3389/fphar.2018.01561Blondeau N, Béraud-Dufour S, Lebrun P, Hivelin C, Coppola T. Sortilin in glucose homeostasis: from accessory protein to key player? Front Pharmacol. 2019;9:1561. doi:10.3389/fphar.2018.01561Andersen OM, Rudolph IM, Willnow TE. Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease. Acta Neuropathol. 2016;132(5):653–665. doi:10.1007/s00401-016-1615-4Andersen OM, Rudolph IM, Willnow TE. Risk factor SORL1: from genetic association to functional validation in Alzheimer’s disease. Acta Neuropathol. 2016;132(5):653–665. doi:10.1007/s00401-016-1615-4Ouyang S, Jia B, Xie W, Yang J, Lv Y. Mechanism underlying the regulation of sortilin expression and its trafficking function. J Cell Physiol. 2020;235(12):8958–8971. doi:10.1002/jcp.29818Ouyang S, Jia B, Xie W, Yang J, Lv Y. Mechanism underlying the regulation of sortilin expression and its trafficking function. J Cell Physiol. 2020;235(12):8958–8971. doi:10.1002/jcp.29818Zhong LY, Cayabyab FS, Tang CK, Zheng XL, Peng TH, Lv YC. Sortilin: a novel regulator in lipid metabolism and atherogenesis. Clin Chim Acta. 2016;460:11–17. doi:10.1016/j.cca.2016.06.013Zhong LY, Cayabyab FS, Tang CK, Zheng XL, Peng TH, Lv YC. Sortilin: a novel regulator in lipid metabolism and atherogenesis. Clin Chim Acta. 2016;460:11–17. doi:10.1016/j.cca.2016.06.013Strong A, Raeder J. Sortilin as a regulator of lipoprotein metabolism. Curr Atheroscler Rep. 2012;14(3):211–218. doi:10.1007/s11883-012-0248-xStrong A, Raeder J. Sortilin as a regulator of lipoprotein metabolism. Curr Atheroscler Rep. 2012;14(3):211–218. doi:10.1007/s11883-012-0248-xNykjaer A, Willnow TE. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 2012;35(4): 261–270.Nykjaer A, Willnow TE. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 2012;35(4): 261–270.Wahe A, Kasmapour B, Schmaderer C, Liebl D, Sandhoff K, Nykjaer A et al. Golgi-to-phagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin. J Cell Sci. 2010;123(14):2502–2511.Wahe A, Kasmapour B, Schmaderer C, Liebl D, Sandhoff K, Nykjaer A et al. Golgi-to-phagosome transport of acid sphingomyelinase and prosaposin is mediated by sortilin. J Cell Sci. 2010;123(14):2502–2511.Willnow TE, Petersen CM, Nykjaer A. VPS 10P-domain receptors — regulators of neuronal viability and function. Nat Rev Neurosci. 2008;9(12):899–909. doi:10.1038/nrg2454Willnow TE, Petersen CM, Nykjaer A. VPS 10P-domain receptors — regulators of neuronal viability and function. Nat Rev Neurosci. 2008;9(12):899–909. doi:10.1038/nrg2454Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, Li X et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012;122(8):2807–2816. doi:10.1172/JCI63563Strong A, Ding Q, Edmondson AC, Millar JS, Sachs KV, Li X et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest. 2012;122(8):2807–2816. doi:10.1172/JCI63563Mortensen MB, Kjolby M, Gunnersen S, Larsen JV, Palmfeldt J, Falk E et al. Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. J Clin Invest. 2014;124(12):5317–5322. doi:10.1172/JCI76002Mortensen MB, Kjolby M, Gunnersen S, Larsen JV, Palmfeldt J, Falk E et al. Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. J Clin Invest. 2014;124(12):5317–5322. doi:10.1172/JCI76002Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A et al. Involvement of TNF-α in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia. 2009;52(5):932–940. doi:10.1007/s00125-009-1273-3Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A et al. Involvement of TNF-α in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia. 2009;52(5):932–940. doi:10.1007/s00125-009-1273-3Oh TJ, Ahn CH, Kim BR, Kim KM, Moon JH, Lim S et al. Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):92. doi:10.1186/s12933-017-0568-9Oh TJ, Ahn CH, Kim BR, Kim KM, Moon JH, Lim S et al. Circulating sortilin level as a potential biomarker for coronary atherosclerosis and diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):92. doi:10.1186/s12933-017-0568-9Goettsch С, Kjolby М, Aikawa E. Sortilin and its multiple roles in cardiovascular and metabolic diseases. Arterioscler Thromb Vasc Biol. 2018;38(1):19–25. doi:10.1161/ATVBAHA.117.310292Goettsch С, Kjolby М, Aikawa E. Sortilin and its multiple roles in cardiovascular and metabolic diseases. Arterioscler Thromb Vasc Biol. 2018;38(1):19–25. doi:10.1161/ATVBAHA.117.310292Kabakova AV, Galyavich AS. Genetic polymorphism and efficiency of lipid-lowering therapy. Bull Contemporary Clin Med. 2016;9(3):75–81.Kabakova AV, Galyavich AS. Genetic polymorphism and efficiency of lipid-lowering therapy. Bull Contemporary Clin Med. 2016;9(3):75–81.Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466(7307):714–719. doi:10.1038/nature09266Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, Sachs KV et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466(7307):714–719. doi:10.1038/nature09266Arvind P, Nair J, Jambunathan S, Kakkar VV, Shanker J. CELSR 2-PSRC 1- SORT1 gene expression and associationwith coronary artery disease and plasma lipid levels in an Asian Indian cohort. J Cardiol. 2014;64(5):339–346. doi:10.1016/j.jjcc.2014.02.012Arvind P, Nair J, Jambunathan S, Kakkar VV, Shanker J. CELSR 2-PSRC 1- SORT1 gene expression and associationwith coronary artery disease and plasma lipid levels in an Asian Indian cohort. J Cardiol. 2014;64(5):339–346. doi:10.1016/j.jjcc.2014.02.012Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ Res. 2018;122(3):433–443. doi:10.1161/CIRCRESAHA.117.312086Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ Res. 2018;122(3):433–443. doi:10.1161/CIRCRESAHA.117.312086Erdmann J, Kessler T, Munoz Venegas L, Schunkert H. A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res. 2018;114(9):1241–1257. doi:10.1093/cvr/cvy084Erdmann J, Kessler T, Munoz Venegas L, Schunkert H. A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res. 2018;114(9):1241–1257. doi:10.1093/cvr/cvy084Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM et al. Genome-wide association of earlyonset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41(3):334–341. doi:10.1038/ng.327Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM et al. Genome-wide association of earlyonset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41(3):334–341. doi:10.1038/ng.327Jones GT et al. A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. Hum Mol Genet. 2013;22(14):2941–2947. doi:10.1093/hmg/ddt141Jones GT et al. A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. Hum Mol Genet. 2013;22(14):2941–2947. doi:10.1093/hmg/ddt141Muendlein A, Geller-Rhomberg S, Saely CH, Winder T, Sonderegger G, Rein P et al. Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. Atherosclerosis. 2009;206(2):494–499. doi:10.1016/j.atherosclerosis.2009.02.040Muendlein A, Geller-Rhomberg S, Saely CH, Winder T, Sonderegger G, Rein P et al. Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. Atherosclerosis. 2009;206(2):494–499. doi:10.1016/j.atherosclerosis.2009.02.040O’Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwang SJ et al. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation. 2011;124(25):2855–2864. doi:10.1161/CIRCULATIONAHA.110.974899O’Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwang SJ et al. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation. 2011;124(25):2855–2864. doi:10.1161/CIRCULATIONAHA.110.974899Goettsch C, Hutcheson JD, Aikawa M, Iwata H, Pham T, Nykjaer A et al. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Invest. 2016;126(4):1323–1336. doi:10.1172/JCI80851Goettsch C, Hutcheson JD, Aikawa M, Iwata H, Pham T, Nykjaer A et al. Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Invest. 2016;126(4):1323–1336. doi:10.1172/JCI80851Gustafsen S, Kjolbi M, Njegaard M, Matteisen M, Lundhede J, Buttenschen N et al. The hypercholesterolemia risk gene SORT1 promotes the secretion of PCSK9. Cell Metab. 2014;19(2):310–318. doi:10.1016/j.cmet.2013.12.006Gustafsen S, Kjolbi M, Njegaard M, Matteisen M, Lundhede J, Buttenschen N et al. The hypercholesterolemia risk gene SORT1 promotes the secretion of PCSK9. Cell Metab. 2014;19(2):310–318. doi:10.1016/j.cmet.2013.12.006Kjolbi M, Andersen OM, Breiderhoff T, Fjerbek AV, Pedersen KM, Madsen P et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of liver lipoprotein export. The Metab Cell. 2010;12(3):213–223. doi:10.1016/j.cmet.2010.08.006Kjolbi M, Andersen OM, Breiderhoff T, Fjerbek AV, Pedersen KM, Madsen P et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of liver lipoprotein export. The Metab Cell. 2010;12(3):213–223. doi:10.1016/j.cmet.2010.08.006Patel KM, Strong A, Tohyama J, Jin X, Morales SR, Bilheimer J et al. Macrophage sortilin promotes the absorption of LDL, the formation of foam cells and the development of atherosclerosis. Circ Res. 2015;116(5):789–796. doi:10.1161/CIRCRESAHA.116.305811Patel KM, Strong A, Tohyama J, Jin X, Morales SR, Bilheimer J et al. Macrophage sortilin promotes the absorption of LDL, the formation of foam cells and the development of atherosclerosis. Circ Res. 2015;116(5):789–796. doi:10.1161/CIRCRESAHA.116.305811Hu D, Yang Y, Peng DQ. Increased sortilin and its independent effect on circulating proprotein convertase subtilisinkexin type 9 (PCSK9) in statin-naive patients with coronary artery disease. Int J Cardiol. 2017;227:61–65. doi:10.1016/j.ijcard.2016.11.064Hu D, Yang Y, Peng DQ. Increased sortilin and its independent effect on circulating proprotein convertase subtilisinkexin type 9 (PCSK9) in statin-naive patients with coronary artery disease. Int J Cardiol. 2017;227:61–65. doi:10.1016/j.ijcard.2016.11.064Goettsch C, Iwata H, Hutcheson JD, O’Donnell CJ, Chapurlat R, Cook NR et al. Serum sortilin associates with aortic calcification and cardiovascular risk in men. Arterioscler Thromb Vasc Biol. 2017;37:1005–1011. doi:10.1161/ATVBAHA.116.308932Goettsch C, Iwata H, Hutcheson JD, O’Donnell CJ, Chapurlat R, Cook NR et al. Serum sortilin associates with aortic calcification and cardiovascular risk in men. Arterioscler Thromb Vasc Biol. 2017;37:1005–1011. doi:10.1161/ATVBAHA.116.308932Biscetti F, Bonadia N, Santini F, Angelini F, Nardella E, Pitocco D et al. Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects. Cardiovasc Diabetol. 2019;18(1):5. doi:10.1186/s12933-019-0805-5Biscetti F, Bonadia N, Santini F, Angelini F, Nardella E, Pitocco D et al. Sortilin levels are associated with peripheral arterial disease in type 2 diabetic subjects. Cardiovasc Diabetol. 2019;18(1):5. doi:10.1186/s12933-019-0805-5Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Michishita I. Effects of statin therapy on plasma proprotein convertase subtilisin/kexin type 9 and sortilin levels in statin naive patients with coronary artery disease. J Atheroscler Thromb. 2016;23(7):848–856. doi:10.5551/jat.33407Nozue T, Hattori H, Ogawa K, Kujiraoka T, Iwasaki T, Michishita I. Effects of statin therapy on plasma proprotein convertase subtilisin/kexin type 9 and sortilin levels in statin naive patients with coronary artery disease. J Atheroscler Thromb. 2016;23(7):848–856. doi:10.5551/jat.33407Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. doi:10.1038/ncomms6068Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. doi:10.1038/ncomms6068Vrablik M, Khubachek Ya, Dlouha D, Lanska V, Rynekrova J, Zlatolavek L. Influence of variants within seven candidate genes on the effectiveness of statin treatment. Physiol Res. 2012;61(6):609–617. doi:10.33549/physiolres.932341Vrablik M, Khubachek Ya, Dlouha D, Lanska V, Rynekrova J, Zlatolavek L. Influence of variants within seven candidate genes on the effectiveness of statin treatment. Physiol Res. 2012;61(6):609–617. doi:10.33549/physiolres.932341Shirts BH, Hasstedt SJ, Hopkins PN, Hunt SC. Assessment of gene interactions with age in HDL cholesterol, LDL cholesterol, and triglycerides: the effect of SORT1 polymorphism on LDL cholesterol is age dependent. Atherosclerosis. 2011;217(1):139–141. doi:10.1016/j.atherosclerosis.2011.03.008Shirts BH, Hasstedt SJ, Hopkins PN, Hunt SC. Assessment of gene interactions with age in HDL cholesterol, LDL cholesterol, and triglycerides: the effect of SORT1 polymorphism on LDL cholesterol is age dependent. Atherosclerosis. 2011;217(1):139–141. doi:10.1016/j.atherosclerosis.2011.03.008Затейщиков Д. А., Минушкина Л. О., Чумакова О. С., Евдокимова М.А., Зотова И.В., Сидоренко Б.А. Генетические исследования в кардиологии: прогнозирование риска неблагоприятных исходов и проблема персонализированного лечения. Кремлевская медицина. 2014;1:84–91.Zateishchikov DA, Minushkina LO, Chumakova OS, Evdokimova MA, Zotova IV, Sidorenko BA. Genetic research in cardiology: predicting the risk of adverse outcomes and the problem of personalized treatment. Kremlin Med. 2014;1:84–91. In RussianKjolby M, Nielsen MS, Petersen CM. Sortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular disease. Curr Atheroscler Rep. 2015 Apr;17(4):496. doi:10.1007/s11883-015-0496-7Kjolby M, Nielsen MS, Petersen CM. Sortilin, encoded by the cardiovascular risk gene SORT1, and its suggested functions in cardiovascular disease. Curr Atheroscler Rep. 2015 Apr;17(4):496. doi:10.1007/s11883-015-0496-7Clark J, Koschinsky M, Marlys L. Apolipoprotein(a) Secretion is Modulated by Sortilin, Proprotein Convertase Subtilisin/Kexin Type 9, and Microsomal Triglyceride Transfer Protein. 2019. Electronic Thesis and Dissertation Repository. 6310. URL:https://ir.lib.uwo.ca/etd/6310Clark J, Koschinsky M, Marlys L. Apolipoprotein(a) Secretion is Modulated by Sortilin, Proprotein Convertase Subtilisin/Kexin Type 9, and Microsomal Triglyceride Transfer Protein. 2019. Electronic Thesis and Dissertation Repository. 6310. URL:https://ir.lib.uwo.ca/etd/6310Coutinho MF, Bourbon M, Prata MJ, Alves S. Sortilin and the risk of cardiovascular diseases. Rev Port Cardiol. 2013; 32(10):793–799. English, Portuguese. doi:10.1016/j.repc.2013.02.006Coutinho MF, Bourbon M, Prata MJ, Alves S. Sortilin and the risk of cardiovascular diseases. Rev Port Cardiol. 2013; 32(10):793–799. English, Portuguese. doi:10.1016/j.repc.2013.02.006Chen C, Li J, Matye DJ, Wang Y, Li T. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J Lipid Res. 2019;60(3):539–549. doi:10.1194/jlr.M089789Chen C, Li J, Matye DJ, Wang Y, Li T. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J Lipid Res. 2019;60(3):539–549. doi:10.1194/jlr.M089789Ogawa K, Ueno T, Iwasaki T, Kujiraoka T, Ishihara M, Kunimoto S et al. Soluble sortilin is released by activated platelets and its circulating levels are associated with cardiovascular risk factors. Atherosclerosis. 2016;249:110–115. doi:10.1016/j.atherosclerosis.2016.03.041Ogawa K, Ueno T, Iwasaki T, Kujiraoka T, Ishihara M, Kunimoto S et al. Soluble sortilin is released by activated platelets and its circulating levels are associated with cardiovascular risk factors. Atherosclerosis. 2016;249:110–115. doi:10.1016/j.atherosclerosis.2016.03.041Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin. Chim. 2013;424:245–252. doi:10.1016/j.cca.2013.06.006Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin. Chim. 2013;424:245–252. doi:10.1016/j.cca.2013.06.006Turner MD, Nejay B, Hirst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cellular signaling and inflammatory diseases. Biochim Biophys Acta. 2014;1843(11):2563–2582. doi:10.1016/j.bbamcr.2014.05.014Turner MD, Nejay B, Hirst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cellular signaling and inflammatory diseases. Biochim Biophys Acta. 2014;1843(11):2563–2582. doi:10.1016/j.bbamcr.2014.05.014Libby P, Lichtman A, Hansson GK. Immune effector mechanisms involved in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092–1104. doi:10.1016/j.immuni.2013.06.009Libby P, Lichtman A, Hansson GK. Immune effector mechanisms involved in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092–1104. doi:10.1016/j.immuni.2013.06.009Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014;129(1):77–86. doi:10.1161/CIRCULATIONAHA.113.003625Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS et al. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014;129(1):77–86. doi:10.1161/CIRCULATIONAHA.113.003625Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311(3):271–278.Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311(3):271–278.Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–713. doi:10.1016/S0140-6736(13)61754-7Joshi NV, Vesey AT, Williams MC, Shah ASV, Calvert PA, Craighead FHM et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383(9918):705–713. doi:10.1016/S0140-6736(13)61754-7Vengrenyuk Y, Carlier S, Xanthos S, Cardoso L, Ganatos P, Virmani R et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci USA. 2006;103(40):14678–14683. doi:10.1073/pnas.0606310103Vengrenyuk Y, Carlier S, Xanthos S, Cardoso L, Ganatos P, Virmani R et al. A hypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc Natl Acad Sci USA. 2006;103(40):14678–14683. doi:10.1073/pnas.0606310103Kelly-Arnold A, Maldonado N, Laudier D, Aikawa E, Cardoso L, Weinbaum S. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad Sci USA. 2013;110(26):10741–10746. doi:10.1073/pnas.1308814110Kelly-Arnold A, Maldonado N, Laudier D, Aikawa E, Cardoso L, Weinbaum S. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad Sci USA. 2013;110(26):10741–10746. doi:10.1073/pnas.1308814110Møller PL, Rohde PD, Winther S, Breining P, Nissen L, Nykjaer A et al. Sortilin as a biomarker for cardiovascular disease revisited. Front Cardiovasc Med. 2021;8:652584. doi:10.3389/fcvm.2021.652584Møller PL, Rohde PD, Winther S, Breining P, Nissen L, Nykjaer A et al. Sortilin as a biomarker for cardiovascular disease revisited. Front Cardiovasc Med. 2021;8:652584. doi:10.3389/fcvm.2021.652584

The authors declare that there are no conflicts of interest present.